Literature DB >> 33187456

Neurotoxicity of poly(propylene imine) glycodendrimers.

Ida Franiak-Pietryga1,2,3, Barbara Ziemba1,2, Hanna Sikorska4, Magdalena Jander2, Dietmar Appelhans5, Maria Bryszewska6, Maciej Borowiec1.   

Abstract

Published results of studies on poly(propylene imine) (PPI) dendrimers indicate their potential use in the treatment of brain cancer or neurodegenerative diseases due to their ability to cross the blood-brain barrier. However, depending on dose, neurotoxicity may occur. Here, we discuss the impact of maltotriose modified PPI dendrimers on rat's nervous system. Wistar rats were treated intravenously for 14 consecutive days with densely (dense-shell; DS) and partly (open-shell; OS) modified PPI dendrimers at doses established as safe in the previous experiment following a single DS or OS administration. The examination included an estimation of the motility and the clinical symptoms of the respiratory, nervous, and cardiovascular systems. Both DS and OS glycodendrimers (GDs) induced adverse effects at the doses tested. Multiple administrations of PPI-OS had a detrimental influence on rats' survival. These findings suggest that the dendrimers adversely influence the nervous system and their toxic effects accumulate over time. In PPI-DS treated animals, the harmful effects were less severe but still present. However, with each treatment day, the clinical symptoms in both groups were less severe as if the animals developed tolerance to GDs. We hypothesize that the neurotoxicity of tested dendrimers is related to nanoparticles-induced autophagy.

Entities:  

Keywords:  Poly(propylene imine); autophagy; dendrimers; in vivo; neurotoxicity

Year:  2020        PMID: 33187456     DOI: 10.1080/01480545.2020.1843472

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  1 in total

Review 1.  Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine.

Authors:  Xiang Li; Abid Naeem; Shanghua Xiao; Lei Hu; Jing Zhang; Qin Zheng
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.